Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the congress on 6 July 2023, from 17:00 – 18:00 CET, given by Prof. Dr. Mohamad Mohty, Professor and Head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). If you would like to attend, click here and register now! The European Hematology Association (EHA) 2023 hybrid congress took place from…
Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:
The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, was held in Vienna, Austria from 9 June to 12 June 2022 in a hybrid format. Myeloma Patients Europe (MPE) attended EHA 2022 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting.
As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare. The survey seeks to understand the perspectives of myeloma and AL amyloidosis patients, as well as haematologists, on the diagnosis challenges. The survey will take approximately 5 minutes to complete and is…
The world’s largest haematology conference will be held in person and virtually this year from the 11th to 14th of December. Despite the continued difficulties and limitations posed by the coronavirus pandemic, this year’s American Society of Haematology Annual Meeting will feature, more than 200 abstracts in myeloma and AL amyloidosis.
MPE presents its poster on the impact of COVID-19 on the treatment and care of patients with myeloma and AL amyloidosis at IMW 2021
As the SARS-CoV-2 (COVID-19) pandemic unfolded in 2020, Myeloma Patients Europe (MPE) became aware that the healthcare, treatment, and lives of myeloma and AL amyloidosis patients and their families were impacted by new health policies and national restrictions related to COVID-19.
Last March, a number of hematology patient associations, including Myeloma Patients Europe (MPE), coordinated by the Acute Leukemia Advocates Network, wrote a letter to the American Society of Hematology (ASH) that patient advocates need free access to the ASH Annual meeting. The message was heard and non-profit patient advocates (employees and volunteers) from registered patient organisations can now apply to attend the 63rd ASH Annual Meeting in December.